Emyria delighted to be accepted into prestigious US pain initiative



Melbourne, Victoria - News Direct - 30 November 2022 -

PressReleaseTMPXyNU9Y.jpg


Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health's (NIH) Preclinical Screening Platform for Pain program. The NIH's National Institute of Neurological Disorders and Stroke (NINDS) — also the leading funder of neurological research in the US — will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria

發行人全權負責本公告的內容
來源:

Emyria Ltd

類別:

Business

 
發佈於

30 Nov 2022

立即聯繫 Media OutReach

立即聯繫我們